Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver

NCT00019760 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00019760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00019760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 1999
Completion date
March 31, 2002
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer